Latest Osteoarthritis News

Page 2 of 2
Paradigm Biopharmaceuticals has acquired Proteobioactives, securing global rights to an oral combination therapy targeting early-stage osteoarthritis in humans and animals, complementing its injectable PPS phase 3 program.
Ada Torres
Ada Torres
26 June 2025
Paradigm Biopharmaceuticals has reached key milestones in its global Phase 3 trial for knee osteoarthritis, activating its first Australian clinical site and enrolling the first patient. With multiple sites in Australia and the US preparing for recruitment, the trial is advancing steadily toward critical data readouts.
Ada Torres
Ada Torres
3 June 2025
Paradigm Biopharmaceuticals has secured centralised US ethics approval for its pivotal Phase 3 trial of injectable pentosan polysulfate sodium (iPPS) targeting moderate to severe knee osteoarthritis, setting the stage for patient enrolment in Q3 2025.
Ada Torres
Ada Torres
15 May 2025
Paradigm Biopharmaceuticals has secured ethics approval and appointed a CRO to launch its global phase 3 trial for injectable Pentosan Polysulfate Sodium in knee osteoarthritis, while initiating a substantial capital raising program.
Ada Torres
Ada Torres
29 Apr 2025
Paradigm Biopharmaceuticals has launched a Loyalty and Piggyback Options program aimed at rewarding shareholders and raising up to $111.96 million to support its pivotal Phase III clinical trial.
Victor Sage
Victor Sage
31 Jan 2025
Paradigm Biopharmaceuticals has appointed Advanced Clinical as the Clinical Research Organisation for its critical Phase 3 trial targeting knee osteoarthritis pain, setting the stage for patient recruitment and dosing in Q2 2025.
Ada Torres
Ada Torres
31 Jan 2025
Paradigm Biopharmaceuticals has secured FDA clearance for its phase 3 knee osteoarthritis trial and raised $16 million to fund its next clinical steps, positioning the company for a pivotal year ahead.
Ada Torres
Ada Torres
30 Jan 2025
Cynata Therapeutics reports encouraging Phase 1 results for its diabetic foot ulcer treatment CYP-006TK, alongside a strengthened balance sheet and ongoing clinical progress.
Ada Torres
Ada Torres
30 Jan 2025
Paradigm Biopharmaceuticals has secured a $6.3 million R&D Tax Incentive refund, lifting its cash reserves to $31 million and reinforcing its push into Phase 3 osteoarthritis clinical trials.
Victor Sage
Victor Sage
24 Jan 2025